What was studied?
This 12-month study enrolled 404 people with HIV and excess abdominal fat. After a six-month randomized phase, participants receiving tesamorelin were rerandomized to continue or change to placebo, while the initial placebo group changed treatment.
What did the researchers report?
The initial comparison showed reduced visceral fat with tesamorelin. The extension examined maintenance and reversal of that response, alongside body image, IGF-I, glucose and safety measurements.
What are the limits?
Extension results answer a continuation question and should not be presented as a permanent change after stopping. This publication reports a particular phase 3 trial, distinct from the earlier 412-participant study. Neither trial establishes equivalence of laboratory catalog vials to the pharmaceutical study product.
Original editorial summary by Sulan Peptide. Based on the source abstract; consult the full paper for methods, analyses, funding and disclosures.